Pfizer enters Alnylam, Ionis' TTR turf with early approval for cardiomyopathy drug, carrying a $225K price tag
Pfizer is set to pull its weight in transthyretin-mediated amyloidosis, a field that has so far been Alnylam and Ionis’ turf.
Transthyretin (TTR) is a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
